

**Supplementary Table 1 – Baseline characteristics of the cohort**

<b>Variables</b> (median, range)	<b>ALF (n=30)</b>	<b>ACLF (n=34)</b>	<b>Stable cirrhosis (n=8)</b>	<b>p-value</b> (ALF vs. ACLF)	<b>p-value</b> (ACLF vs. stable cirrhosis)
Concomittant disease(s)	Psychiatric disorder 13 Alcohol abuse 10 Substance abuse 2 Steroid abuse 1 Asthma bronchiale 2 COPD 1 Hypertension 2 Eclampsia 1 Diabetes mellitus 2 Pervious neoplasia 1 Fatty liver 1 None 8	Alcohol abuse 9 psychiatric disorder 6 Coronary artery disease 4 Arterial hypertension 7 Diabetes mellitus 7 Dyslipidaemia 3 Chronic kidney disease 3 Asthma/COPD 3 Brain aneurysm 1 Ulcerative colitis 1 Dilatative cardiopathy 1 Obesity 2 Previous portal vein thrombosis 3 Hypothyroidism 1 Polycythaemia 1 None 9	none 3 Diabetes mellitus 3 Arterial hypertension 2 Coronary artery disease 1 Valvular heart disease 1 Retinal eye dystrophy 1		
Heartrate (bpm)	92 (52 – 128)	85 (59 - 129)	75 (48 – 83)	0.57	<b>0.0082</b>
Use of vasoactive agents [%]	Total: 16 [53.3] NE: 13 [43.3] NE and Vasopressin: 2 [6.7] Terlipressin: 1 [3.3]	Total: 22 [64.7] NE: 8 [23.5] Terlipressin: 6 [17.6] NE and Terlipressin: 5 [14.7] NE and Vasopressin: 2 [5.9] NE and Terlipressin and Dobutamine: 1 [2.9]	0	0.36	<b>0.001</b>
Respiratory rate (/min)	18 (8 – 28)	18 (10 - 26)	16 (15 – 19)	0.78	0.51
Temperature (°C)	36.5 (33.7 – 38.8)	36.6 (34.6 - 45.7)	36.7 (36.0 – 37.1)	0.28	0.47
Hepatic encephalopathy (HE)	Grade I-II 11 Grade III-IV 9 Grade not specified 5 No HE 5	Grade I-II 12 Grade III-IV 7 Grade not specified 8 No HE 7	Grade I-II 2 No HE 5	0.69	<b>0.003</b>
Urea (mmol/l)	7.7 (1.1 – 24)	9.3 (1.2 - 27.2)	7.0 (3.1 – 88)	0.28	0.23
Potassium (mmol/l)	4.1 (3.2 – 5.5)	4.2 (3.3 - 5.9)	4.2 (3.2 – 5.1)	0.09	0.50
Haemoglobin (g/l)	98 (76 – 164)	87 (65 - 130)	121 (96 – 152)	0.08	<b>0.0003</b>